Guidelines for clinical treatment of early course schizophrenia

Current Psychiatry Reports

Volumn 8, Issue 4, 2006, Pages 329-334

  Keshavan, Matcheri S ^a   Roberts, Mary ^b   Wittmann, Daniela ^b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; HALOPERIDOL; LORAZEPAM; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; ZIPRASIDONE;

ADJUVANT THERAPY; AGITATION; BEHAVIOR THERAPY; CARDIOVASCULAR DISEASE; COGNITIVE THERAPY; COMMUNITY CARE; COST EFFECTIVENESS ANALYSIS; DELUSION; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; EMPLOYMENT; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; FAMILY RELATION; HEALTH CARE ACCESS; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; INSULIN RESISTANCE; PATIENT AUTONOMY; PRACTICE GUIDELINE; PSYCHOEDUCATION; PSYCHOSOCIAL CARE; REVIEW; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SELF CONCEPT; SEXUAL DYSFUNCTION; SIDE EFFECT; SOCIAL ADAPTATION; SUICIDAL BEHAVIOR; TARDIVE DYSKINESIA; THERAPY RESISTANCE; TREATMENT PLANNING; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; COGNITIVE THERAPY; DRUG ADMINISTRATION SCHEDULE; EARLY DIAGNOSIS; HUMANS; PATIENT EDUCATION; PATIENT EDUCATION AS TOPIC; PRACTICE GUIDELINES; PRACTICE GUIDELINES AS TOPIC; SCHIZOPHRENIA; TIME FACTORS;

EID: 33747189233     PISSN: 15233812     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11920-006-0070-7     Document Type: Review

References (34)

1. Perkins DO, Gu H, Boteva K, Lieberman JA: Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and metaanalysis. Am J Psychiatry 2005, 162:1785-1804.
2. Thompson PM, Vidal C, Giedd JN, et al.: Mapping adolescent brain change reveals dynamic wave of accelerated gray matter loss in very early-onset schizophrenia. Proc Natl Acad Sci U S A 2001, 98:11650-11655.
3. McGorry PD, Yung AR, Phillips LJ, et al.: Controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 2002, 59:921-928.
4. Petersen L, Jeppesen P, Thorup A, et al.: Andomised multicentre trial of integrated versus standard treatment for patients with a first episode of psychotic illness. BMJ 2005, 331:602.
5. American Psychiatric Association: Practice Guidelines for the Treatment of Patients with Schizophrenia. Arlington, VA: American Psychiatric Press; 2004.
6. Treatment of schizophrenia. The Expert Consensus Panel for Schizophrenia. J Clin Psychiatry 1996, 57(Suppl 12B):3-58.
7. Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophrenia and Related Disorders: Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust N Z J Psychiatry 2005, 39:1-30.
8. Lehman AF, Kreyenbuhl J, Buchanan RW, et al.: The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations. Schizophr Bull 2004, 30:193-217.
9. International clinical practice guidelines for early psychosis: IEPA writing group. Br J Psychiatry 2005, 187(Suppl 48): s120-s124.
10. Yung AR, Phillips LJ, McGorry PD, et al.: Prediction of psychosis: a step towards indicated prevention of schizophrenia. Br J Psychiatry 1998, 172(Suppl 33):14-20.
11. Gleeson J, Larsen T, McGorry P: Psychological treatment in pre- and early psychosis. J Am Acad Psychoanal Dyn Psychiatry 2003, 31:229-245.
12. Robinson DG, Woerner MG, Delman HM, Kane JM: Pharmacological treatments for first-episode schizophrenia. Schizophr Bull 2005, 31:705-722.
13. Frank AF, Gunderson G: The role of the therapeutic alliance in the treatment of schizophrenia. Relationship to course and outcome. Arch Gen Psychiatry 1990, 47:228-236.
14. Lieberman JA, Stroup TS, McEvoy JP, et al.: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353:1209-1223.
15. Fortner RB, Steel C: The history and outcome of my encounter with schizophrenia. In Psychological and Social Aspects of Psychiatric Disability. Edited by Spaniol L, Gagne C, Koehler M. Boston: Boston University Center for Psychiatric Rehabilitation; 1997:112-118.
16. Hogarty GE: Personal Therapy for Schizophrenia and Related Disorders: A Guide to Individualized Treatment. New York: Guilford Publications; 2002.
17. Csernansky JG, Mahmoud R, Brenner R: Risperidone-USA-79 Study Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002, 346:16-22. [Published erratum appears in N Engl J Med 2002, 346:1424.]
18. Casey DE: Metabolic issues and cardiovascular disease in patients with psychiatric disorders. Am J Med 2005, 118(Suppl 2):15S-22S.
19. Weiden PJ: Switching antipsychotics: an updated review with a focus on quetiapine. J Psychopharmacol 2006, 20:104-118.
20. McFarlane WR: Multifamily Groups in the Treatment of Severe Psychiatric Disorders. New York: Guilford Press; 2002.
21. McFarlane WR, Dixon I, Lukens E, Lucksted A: Family psychoeducation in schizophrenia: a review of the literature. J Marital Fam Ther 2003, 29:223-245.
22. Addington J, Williams J, Young J, Addington D: Suicidal behavior in early psychosis. Acta Psychiatr Scand 2004, 109:116-120.
23. Kingdon DG, Turkington D: Cognitive Psychotherapy of Schizophrenia. New York: Guilford Press; 2005.
24. Linszen D, Dingemans P, Van der Does J, et al.: Treatment, expressed emotion and relapse in recent onset schizophrenic disorders. Psychol Med 1996, 26:333-342.
25. Addington J, Burnett P: Working with families in the early stages of psychosis. In Psychological Interventions in Early Psychosis. Edited by Gleeson JFM, McGorry PD. Hoboken, NJ: John Wiley & Sons; 2004:99-116.
26. Tait L, Birchwood M, Trower P: Adapting to the challenge of psychosis: personal resilience and the use of sealing-over (avoidant) coping strategies. Br J Psychiatry 2004, 185:410-415.
27. Perkins DO: Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 2002, 63:1121-1126.
28. Kemp R, Kirov G, Everitt B, et al.: Randomised controlled trial of compliance therapy. 18-month follow-up. Br J Psychiatry 1998, 172:413-419.
29. Edwards J, Wade D, Herrmann-Doig T, Gee D: Psychological treatment of persistent positive symptoms in young people with first-episode psychosis. In Psychological Interventions in Early Psychosis. Edited by Gleeson JFM, McGorry PD. Hoboken, NJ: John Wiley & Sons; 2004:191-208.
30. Bellack AS, Mueser KT, Gingerich S, Agresta J: Social Skills Training for Schizophrenia. A Step-by-Step Guide, edn 2. New York: Guilford Press; 2004.
31. Hogarty GE, Flesher S, Ulrich Carter M, et al.: Cognitive enhancement therapy for schizophrenia. Arch Gen Psychiatry 2004, 61:866-876.
32. Roder V, Zorn P, Muller D, Brenner HD: Improving recreational, residential, and vocational outcomes for patients with schizophrenia. Psychiatr Serv 2001, 52:1439-1441.
33. Marshall M, Lockwood A: Assertive community treatment for people with severe mental disorders. Cochrane Database Syst Rev 2000, 2:CD001089.
34. Hinton M, Elkins K, Edwards J, Donovan K: Cannabis and Psychosis Treatment Manual. Melbourne, Australia: Early Psychosis Prevention and Intervention Center; 2002.